---
title: "SPAC Brookline Capital Acquisition II files for a $100 million IPO, targeting healthcare"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270363232.md"
description: "Brookline Capital Acquisition II, a SPAC targeting healthcare and defense, filed for a $100 million IPO. The company plans to offer 10 million units at $10 each, with each unit comprising one share of common stock and a right to receive one-tenth of a share upon a business combination. Led by Chairman Samuel Wertheimer, the SPAC aims to list on Nasdaq under the symbol BCACU. Brookline Capital Markets is the sole bookrunner."
datetime: "2025-12-19T23:48:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270363232.md)
  - [en](https://longbridge.com/en/news/270363232.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270363232.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/270363232.md) | [English](https://longbridge.com/en/news/270363232.md)


# SPAC Brookline Capital Acquisition II files for a $100 million IPO, targeting healthcare

Brookline Capital Acquisition II, a blank check company formed by Brookline Capital Markets targeting healthcare and defense, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

The company plans to raise $100 million by offering 10 million units at $10. Each unit consists of one share of common stock and one right to receive one-tenth of one share upon the completion of an initial business combination.

Brookline Capital Acquisition II is led by **Chairman Samuel Wertheimer**, a Senior Scientific Advisor at Brookline Capital Markets. He is joined by **CEO and Director Patrick Sturgeon**, a Managing Partner at Brookline Capital Markets, and **CFO and President Dimitre Genov**, also a Managing Director at Brookline Capital. The SPAC plans to target a business in the healthcare and defense technology industries.

Management's previous SPAC, Brookline Capital Acquisition, merged with **Apexigen** (formerly Nasdaq: APGN) in 2022, which was delisted after being acquired by Pyxis Oncology in 2023.

The New York, NY-based company was founded in 2025 and plans to list on the Nasdaq under the symbol BCACU. Brookline Capital Markets is the sole bookrunner on the deal.

## 相關資訊與研究

- [TK Elevator keeps IPO option on the table](https://longbridge.com/zh-HK/news/281135641.md)
- [OpenAI raises $122bn, edging closer to an IPO](https://longbridge.com/zh-HK/news/281242932.md)
- [QDRO Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering | QADR Stock News](https://longbridge.com/zh-HK/news/280691255.md)
- [Rentomojo IPO: Accel India IV (Mauritius) Limited to sell 7.8 mln shares](https://longbridge.com/zh-HK/news/280835904.md)
- [SM Reit scheme PropShare Celestia's ₹244 crore IPO to open on April 10](https://longbridge.com/zh-HK/news/280996683.md)